<?xml version="1.0" encoding="UTF-8"?>
<p>Among all 353 assessed regular outpatient medications, antiepileptic drugs (carbamazepine [5 patients], eslicarbazepine [1 patient], and oxcarbazepine [1 patient]), St. John’s wort (1 patient), and rifampicin (1 patient) were identified as the medications with the highest potential for DDIs, being contraindicated for coadministration with ≥10 of the 14 different antiviral regimens/substances (
 <xref ref-type="supplementary-material" rid="sup1">Supplementary Table 4</xref>). The main reason for the contraindications was a strong CYP induction by these substances, which would accelerate the metabolism of the antivirals and risk the efficacy of treatment when coadministered.
</p>
